Clinical Report: Evaluation of H101 with PD-1 Inhibitors in Gastric Cancer

Overview

This study evaluates the short-term efficacy and safety of recombinant human adenovirus type 5 (H101) combined with S-1 and oxaliplatin (SOXP regimen) in neoadjuvant treatment for locally advanced gastric cancer (LAGC). Results indicate an objective response rate (ORR) of 96% and a pathological complete response (pCR) rate of 40%, with manageable adverse events.

Background

Gastric cancer has a high incidence and mortality rate, particularly in China, where it accounts for a significant proportion of global cases. Current treatment strategies, including systemic chemotherapy, have shown limited efficacy.

Data Highlights

Key Findings

• 32% of patients achieved a complete response (CR).
• 64% of patients achieved a partial response (PR).
• The objective response rate (ORR) was 96%.
• The pathological complete response (pCR) rate was 40%.
• No grade 4 adverse events were observed, indicating manageable safety.
• 100% R0 resection rate was achieved post-treatment.

Clinical Implications

The combination of H101 with the SOXP regimen demonstrates a high response rate and favorable safety profile in patients with LAGC.

Conclusion

The study indicates that H101 combined with the SOXP regimen shows high efficacy and manageable safety in LAGC.

Related Resources & Content

1. Gastric Cancer — Comparison of SOX with sintilimab versus SOX monotherapy in the perioperative treatment of locally advanced gastric cancer: a propensity score-matched study
2. The ASCO Post — Locally Advanced Gastric Cancer: Adjuvant or Perioperative Therapy With D2 Resection
3. Gastric Cancer — Phase 2 Trial of Neoadjuvant Camrelizumab, Trastuzumab, and Chemotherapy in Patients with HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm Study
4. The ASCO Post — Neoadjuvant Immunotherapy May Benefit Patients With Early-Stage NSCLC
5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
6. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585)
7. Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. | Journal of Clinical Oncology